Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Reisa Anne Sperling, M.D.

Co-Author

This page shows the publications co-authored by Reisa Sperling and Rebecca Amariglio.
Connection Strength

10.036
  1. Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data. J Prev Alzheimers Dis. 2021; 8(3):257-262.
    View in: PubMed
    Score: 0.938
  2. Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. J Alzheimers Dis. 2020; 75(4):1437-1446.
    View in: PubMed
    Score: 0.875
  3. Amyloid-associated increases in longitudinal report of subjective cognitive complaints. Alzheimers Dement (N Y). 2018; 4:444-449.
    View in: PubMed
    Score: 0.798
  4. Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease. Alzheimers Dement (Amst). 2021; 13(1):e12243.
    View in: PubMed
    Score: 0.247
  5. Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline. Ann Neurol. 2020 11; 88(5):921-932.
    View in: PubMed
    Score: 0.229
  6. Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults. Neuroimage Clin. 2019; 24:102097.
    View in: PubMed
    Score: 0.217
  7. Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. Alzheimers Dement (Amst). 2019 Dec; 11:670-678.
    View in: PubMed
    Score: 0.215
  8. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurol. 2019 05 01; 76(5):542-551.
    View in: PubMed
    Score: 0.209
  9. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019 02; 85(2):181-193.
    View in: PubMed
    Score: 0.205
  10. An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. J Alzheimers Dis. 2019; 68(3):1161-1170.
    View in: PubMed
    Score: 0.204
  11. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global ß-Amyloid Burden. JAMA Neurol. 2017 12 01; 74(12):1455-1463.
    View in: PubMed
    Score: 0.189
  12. Subjective cognitive concerns are associated with objective memory performance in Caucasian but not African-American persons. Age Ageing. 2017 11 01; 46(6):988-993.
    View in: PubMed
    Score: 0.188
  13. Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging. Neuroimage Clin. 2017; 15:408-414.
    View in: PubMed
    Score: 0.183
  14. Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden. Neurology. 2017 May 02; 88(18):1759-1767.
    View in: PubMed
    Score: 0.181
  15. Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease. Neuropsychologia. 2017 05; 99:343-349.
    View in: PubMed
    Score: 0.181
  16. Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology. 2017 Apr 11; 88(15):1431-1438.
    View in: PubMed
    Score: 0.180
  17. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid ß. Alzheimers Dement. 2017 Sep; 13(9):1004-1012.
    View in: PubMed
    Score: 0.180
  18. Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. JAMA Psychiatry. 2016 Dec 01; 73(12):1230-1237.
    View in: PubMed
    Score: 0.177
  19. The influence of demographic factors on subjective cognitive concerns and beta-amyloid. Int Psychogeriatr. 2017 04; 29(4):645-652.
    View in: PubMed
    Score: 0.175
  20. Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. JAMA Neurol. 2016 Oct 01; 73(10):1185-1191.
    View in: PubMed
    Score: 0.175
  21. A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. J Mol Neurosci. 2016 Nov; 60(3):354-361.
    View in: PubMed
    Score: 0.173
  22. The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. J Prev Alzheimers Dis. 2016 Mar; 3(1):8-12.
    View in: PubMed
    Score: 0.168
  23. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016 Jan; 79(1):110-9.
    View in: PubMed
    Score: 0.165
  24. Subjective cognitive concerns, amyloid-ß, and neurodegeneration in clinically normal elderly. Neurology. 2015 Jul 07; 85(1):56-62.
    View in: PubMed
    Score: 0.159
  25. Establishing Clinical Relevance in Preclinical Alzheimer's Disease. J Prev Alzheimers Dis. 2015 Jun; 2(2):85-87.
    View in: PubMed
    Score: 0.159
  26. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 2015 Apr; 72(4):446-54.
    View in: PubMed
    Score: 0.157
  27. Amyloid-ß deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain. 2015 Apr; 138(Pt 4):1023-35.
    View in: PubMed
    Score: 0.156
  28. Synergistic effect of ß-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014 Nov; 71(11):1379-85.
    View in: PubMed
    Score: 0.153
  29. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012 Oct; 50(12):2880-2886.
    View in: PubMed
    Score: 0.131
  30. Validation of the Face Name Associative Memory Exam in cognitively normal older individuals. J Clin Exp Neuropsychol. 2012; 34(6):580-7.
    View in: PubMed
    Score: 0.127
  31. Specific subjective memory complaints in older persons may indicate poor cognitive function. J Am Geriatr Soc. 2011 Sep; 59(9):1612-7.
    View in: PubMed
    Score: 0.123
  32. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011 Jul; 49(9):2776-83.
    View in: PubMed
    Score: 0.121
  33. Association of cortical microstructure with amyloid-ß and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. Mol Psychiatry. 2021 Sep 29.
    View in: PubMed
    Score: 0.062
  34. Corrigendum to "Stress, resilience, and coping strategies in a sample of community-dwelling older adults during COVID-19" [J. Psychiatr. Res. 138 (2021) 176-185]. J Psychiatr Res. 2021 Oct; 142:167-170.
    View in: PubMed
    Score: 0.061
  35. The impact of COVID-19 on the well-being and cognition of older adults living in the United States and Latin America. EClinicalMedicine. 2021 May; 35:100848.
    View in: PubMed
    Score: 0.060
  36. Stress, resilience, and coping strategies in a sample of community-dwelling older adults during COVID-19. J Psychiatr Res. 2021 06; 138:176-185.
    View in: PubMed
    Score: 0.060
  37. Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease. Alzheimers Dement (Amst). 2020; 12(1):e12132.
    View in: PubMed
    Score: 0.059
  38. Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. Alzheimers Dement (Amst). 2020; 12(1):e12118.
    View in: PubMed
    Score: 0.058
  39. Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimers Res Ther. 2020 10 29; 12(1):138.
    View in: PubMed
    Score: 0.058
  40. Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. J Int Neuropsychol Soc. 2021 05; 27(5):426-438.
    View in: PubMed
    Score: 0.058
  41. The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2020 09 10; 12(1):104.
    View in: PubMed
    Score: 0.057
  42. Multiple markers contribute to risk of progression from normal to mild cognitive impairment. Neuroimage Clin. 2020; 28:102400.
    View in: PubMed
    Score: 0.057
  43. The presubiculum links incipient amyloid and tau pathology to memory function in older persons. Neurology. 2020 05 05; 94(18):e1916-e1928.
    View in: PubMed
    Score: 0.056
  44. Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimers Dement. 2020 03; 16(3):552-560.
    View in: PubMed
    Score: 0.055
  45. Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2020 03; 91(3):330-332.
    View in: PubMed
    Score: 0.055
  46. Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. JAMA Netw Open. 2019 08 02; 2(8):e198964.
    View in: PubMed
    Score: 0.053
  47. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease. Alzheimers Res Ther. 2019 01 31; 11(1):14.
    View in: PubMed
    Score: 0.051
  48. Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments. Alzheimers Res Ther. 2019 01 10; 11(1):4.
    View in: PubMed
    Score: 0.051
  49. Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia. J Alzheimers Dis. 2019; 67(2):757-768.
    View in: PubMed
    Score: 0.051
  50. Sex, amyloid, and APOE e4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement. 2018 09; 14(9):1193-1203.
    View in: PubMed
    Score: 0.049
  51. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018 10; 14(10):1281-1292.
    View in: PubMed
    Score: 0.049
  52. The Impact of Awareness of and Concern About Memory Performance on the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease Dementia. Am J Geriatr Psychiatry. 2018 08; 26(8):896-904.
    View in: PubMed
    Score: 0.049
  53. Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci. 2018 03; 21(3):424-431.
    View in: PubMed
    Score: 0.048
  54. A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimer's Disease. J Alzheimers Dis. 2018; 65(1):107-115.
    View in: PubMed
    Score: 0.048
  55. Subjective memory complaints in preclinical autosomal dominant Alzheimer disease. Neurology. 2017 Oct 03; 89(14):1464-1470.
    View in: PubMed
    Score: 0.047
  56. Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. J Alzheimers Dis. 2017; 59(3):975-985.
    View in: PubMed
    Score: 0.044
  57. Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly. J Prev Alzheimers Dis. 2017; 4(2):81-86.
    View in: PubMed
    Score: 0.044
  58. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. J Prev Alzheimers Dis. 2017; 4(2):116-124.
    View in: PubMed
    Score: 0.044
  59. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017 Mar; 13(3):296-311.
    View in: PubMed
    Score: 0.044
  60. Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly. J Alzheimers Dis. 2016 06 18; 53(3):1097-105.
    View in: PubMed
    Score: 0.043
  61. The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease. J Prev Alzheimers Dis. 2015 Dec; 2(4):242-253.
    View in: PubMed
    Score: 0.041
  62. Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease. Neuropsychology. 2016 07; 30(5):624-30.
    View in: PubMed
    Score: 0.041
  63. Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. J Alzheimers Dis. 2015 Sep 24; 48 Suppl 1:S63-86.
    View in: PubMed
    Score: 0.041
  64. Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology. 2015 Jul 07; 85(1):48-55.
    View in: PubMed
    Score: 0.040
  65. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. Neuropsychologia. 2015 Jul; 73:169-75.
    View in: PubMed
    Score: 0.040
  66. Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology. 2015 May 26; 84(21):2153-60.
    View in: PubMed
    Score: 0.040
  67. Harvard Aging Brain Study: Dataset and accessibility. Neuroimage. 2017 01; 144(Pt B):255-258.
    View in: PubMed
    Score: 0.039
  68. Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment. J Alzheimers Dis. 2015; 46(3):727-35.
    View in: PubMed
    Score: 0.039
  69. Functional Activities Questionnaire Items that Best Discriminate and Predict Progression from Clinically Normal to Mild Cognitive Impairment. Curr Alzheimer Res. 2015; 12(5):493-502.
    View in: PubMed
    Score: 0.039
  70. The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. J Alzheimers Dis. 2015; 47(2):421-32.
    View in: PubMed
    Score: 0.039
  71. Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults. J Alzheimers Dis. 2015; 46(1):63-73.
    View in: PubMed
    Score: 0.039
  72. Apathy is associated with lower inferior temporal cortical thickness in mild cognitive impairment and normal elderly individuals. J Neuropsychiatry Clin Neurosci. 2015; 27(1):e22-7.
    View in: PubMed
    Score: 0.038
  73. Subjective cognitive concerns, episodic memory, and the APOE e4 allele. Alzheimers Dement. 2014 Nov; 10(6):752-759.e1.
    View in: PubMed
    Score: 0.038
  74. Development of a psychometrically equivalent short form of the Face-Name Associative Memory Exam for use along the early Alzheimer's disease trajectory. Clin Neuropsychol. 2014; 28(5):771-85.
    View in: PubMed
    Score: 0.037
  75. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014 Nov; 10(6):844-52.
    View in: PubMed
    Score: 0.037
  76. Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry. 2014 Dec; 22(12):1642-51.
    View in: PubMed
    Score: 0.036
  77. SIST-M-IR activities of daily living items that best discriminate clinically normal elderly from those with mild cognitive impairment. Curr Alzheimer Res. 2014; 11(8):785-91.
    View in: PubMed
    Score: 0.036
  78. Everyday cognition scale items that best discriminate between and predict progression from clinically normal to mild cognitive impairment. Curr Alzheimer Res. 2014; 11(9):853-61.
    View in: PubMed
    Score: 0.036
  79. Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review. Alzheimers Res Ther. 2013; 5(6):58.
    View in: PubMed
    Score: 0.036
  80. Apathy is associated with increased amyloid burden in mild cognitive impairment. J Neuropsychiatry Clin Neurosci. 2013; 25(4):302-7.
    View in: PubMed
    Score: 0.034
  81. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci. 2012 Nov 14; 32(46):16233-42.
    View in: PubMed
    Score: 0.033
  82. Activities of daily living: where do they fit in the diagnosis of Alzheimer's disease? Neurodegener Dis Manag. 2012 Oct 01; 2(5):483-491.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.